Author:
Laorden Daniel,Romero David,Domínguez-Ortega Javier
Reference5 articles.
1. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis;Wechsler;N Engl J Med,2017
2. Skin lesions in a patient with asthma;Grillo;Med Clin (Barc),2013
3. Efficacy and safety of benralizumab for patients with severeasthma uncontrolled with high-dosage inhaled corticosteroidsand long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial;Bleecker;Lancet,2016
4. Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab;Chica-Guzmán;Ann Allergy Asthma Immunol,2020
5. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 Identifier NCT04157348. Wechsler M. Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. Study: MANDARA. 2019 Nov 8. Available from: https://clinicaltrials.gov/ct2/show/NCT04157348?term=NCT04157348&draw=1&rank=1 [accessed 28.2.21].